Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 9/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27867016 | 0.84 | TACR1 (0.42) | SCN4A | |
| SCHEMBL7235718 | 0.80 | HRH1 (0.50) | — | |
| SCHEMBL2784864 | 0.79 | DPP4 (0.55) | SCN4ADPP4F2 | |
| SCHEMBL2781359 | 0.79 | DPP4 (0.55) | SCN4ADPP4F2 | |
| SCHEMBL2781356 | 0.79 | DPP4 (0.55) | SCN4ADPP4F2 | |
| SCHEMBL4785073 | 0.79 | CYP2C19 (0.44) | SCN4ADPP4F2 | |
| SCHEMBL8050506 | 0.79 | CYP2C19 (0.44) | SCN4ADPP4F2 | |
| SCHEMBL8067055 | 0.79 | CYP2C19 (0.44) | SCN4ADPP4F2 | |
| SCHEMBL4709939 | 0.78 | SCN4A (0.45) | SCN4ADPP4F2GBA1 | |
| SCHEMBL2675712 | 0.78 | SCN4A (0.45) | SCN4ADPP4F2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0505543-A1 | NOVEL p-SUBSTITUTED PHENYL 4-OXYBUTANE AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRE THERAMEX (MC) | 1992-09-30 | — | — | EP | claimed |
| WO-1992006977-A1 | NOVEL p-SUBSTITUTED PHENYL 4-OXYBUTANE AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRE THERAMEX S.A. (MC) | 1992-04-30 | — | — | WO | claimed |
| US-20230340026-A1 | COMPOUNDS | NEW PHARMA LICENCE HOLDINGS LTD (MT) | 2023-10-26 | — | — | US | disclosed |
| CN-107739331-B | A kind of synthetic method of 2-vhloro-5-chloromethylpyridine | 九江善水科技股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-107739331-A | A kind of synthetic method of the PMC of 2 chlorine 5 | 九江善水科技股份有限公司 | 2018-02-27 | — | — | CN | disclosed |
| US-20180030092-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340026-A1 | COMPOUNDS | BCAT1, BCAT2, CCNT1 | SCN4A 2655/4885DPP4 4753/4885F2 26/4885 |
| US-20180030092-A1 | COMPOUNDS | BCAT1, BCAT2, IL4I1 | SCN4A 2419/4885DPP4 4637/4885F2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.